Vijay Modur

Vijay Modur

Company: Eloxx Pharmaceuticals

Job title: Head of R&D

Seminars:

Discovery of Novel Oncoribosome Selective Protein Translational Inhibitors via Synthetic Modified Macrolides 4:00 pm

The TURBO-ZM platform represents an innovative leap in synthetic chemistry to generate Ribosomal Modulating Agents (RMAs) selective for the oncoribosome RMAs spare normal cells while targeting a subset of cancers addicted to oncoribosome-driven protein translation Proteomic analysis shows extreme susceptibility to protein translation inhibition of highly positively charged proteins that participate in translation initiation and…Read more

day: Day Two

Panel Discussion – Modelling Selectivity – Can we Develop a Model to Map Selectivity Binding? 3:30 pm

How to define selectivity and specificity? How to improve efficient and potent cell, tissue, and disease selectivity? Can we construct a suitable model for selectivity? How to guarantee selective and specific binding of your RNA targeting small molecules?Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.